Navigation Links
Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Date:3/25/2008

tenance of normal heart rhythm following termination of AF. Cardiome announced positive results from a Phase 2a pilot study for vernakalant (oral) in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.

In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC for all indications. Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.

Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQ National Market (CRME).

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing.

Specifically, certain risks and uncertainties that could cause su
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
3. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
4. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
5. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
6. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
9. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
10. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
11. IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013  TechAtlas Group has announced the ... landscape map for the Chronic Kidney Disease (CKD) ... companies with drugs and devices currently on the ... sequelae. (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ... hypertension - renal denervation , diabetic nephropathy ...
(Date:5/17/2013)... /PRNewswire-iReach/ -- The escalation of new biological drugs, ... emphasis on alternate delivery technologies. Alternate delivery technologies ... factors are converging to create both risk ... device partners . These include new classes of ... toward self-administration for chronic diseases, shifting patient demographics ...
(Date:5/17/2013)... 17, 2013 Fuse Science, Inc. (OTCQB: DROP), ( ... is developing new, patent-pending technologies poised to redefine how consumers ... will hold a business update teleconference and webcast for shareholders ... 2013 at 4:30 PM ET. Fuse Science, ... the call and will be joined by Rubin ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2
... CVS ) is leading the private-sector effort ... several recently introduced initiatives now set to deliver long-term ... Operating Officer Larry Merlo and other senior executives will ... York City today. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) ...
... Oct. 7 A new women,s health, whole soy ... of moderate to severe hot flashes and reduced muscle ... kind among postmenopausal U.S. women, according to peer-reviewed data ... Menopause Society (NAMS) Annual Meeting.  Also, the first study ...
Cached Medicine Technology:CVS Caremark Ready to Support Patients and Payors Through Coming Era of Health Care Expansion 2CVS Caremark Ready to Support Patients and Payors Through Coming Era of Health Care Expansion 3New Soy-Based Natural S-equol Supplement Reduces Menopausal Hot Flashes, Muscle and Joint Pain in First Study Among U.S. Women 2New Soy-Based Natural S-equol Supplement Reduces Menopausal Hot Flashes, Muscle and Joint Pain in First Study Among U.S. Women 3New Soy-Based Natural S-equol Supplement Reduces Menopausal Hot Flashes, Muscle and Joint Pain in First Study Among U.S. Women 4New Soy-Based Natural S-equol Supplement Reduces Menopausal Hot Flashes, Muscle and Joint Pain in First Study Among U.S. Women 5New Soy-Based Natural S-equol Supplement Reduces Menopausal Hot Flashes, Muscle and Joint Pain in First Study Among U.S. Women 6New Soy-Based Natural S-equol Supplement Reduces Menopausal Hot Flashes, Muscle and Joint Pain in First Study Among U.S. Women 7
(Date:5/19/2013)... 19, 2013 According to a ... and Forecast (2013 – 2018): By Applications (Healthcare ... Technology (CCD, CMOS, Contact IS, Infrared, X-Ray) And ... sensor market was $8.00 billion in 2012 and ... at an estimated CAGR of 3.84% from 2013 ...
(Date:5/19/2013)... May 19, 2013 The report “Feed ... Trends & Forecasts up to 2017” published by MarketsandMarkets, ... with analysis and forecasting of the global volume and ... the driving and restraining factors for the global market ... and challenges. The market is segmented and revenue is ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Americans live ... to the newest American Veterinary Medical Association (AVMA) U.S. ... American dog owners consider their dog a member of ... had said as much five years earlier. , According ... value of the national income dedicated to pets has ...
(Date:5/19/2013)... 2013 The Fat Loss Code program developed ... that help people get in shape, and gain a ... The program also is a natural fat loss system that ... author of this fat loss diet program claimed that The ... help people keep body fat off long-term. After Shawn Stevenson ...
(Date:5/19/2013)... 19, 2013 Agora Health Limited developed by ... guides on how to increase memory power naturally ... method that helps people re-new their entire health from the ... depression caused by a fatigued mind. In addition, the program ... for a lifetime. The author claimed that this program can ...
Breaking Medicine News(10 mins):Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 2Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 3Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3Health News:Weight Loss Secrets | How “The Fat Loss Code” Helps People Gain A Healthy Life And Get In Shape - Health Review 2Health News:How To Increase Memory Power | How “Agora Health Limited” Helps People Improve Their Memory Naturally And Effectively – Health Review 2
... emergence of minimally invasive surgery procedures in operating theatres. ... leaves much to be desired. Researcher Magdalena Chmarra has ... training system which records and analyses the surgeon,s movements. ... time, an objective benchmark for measuring a surgeon,s basic ...
... ICU, and All-Private Hospital WingNEW ORLEANS, Jan. 12 At ... on Monday, January 12, 2009 , DHH Secretary Alan ... Ochsner Baptist Medical Center and the community to celebrate the ... room hospital wing at 2700 Napoleon Avenue in ...
... NEW YORK and SAN FRANCISCO, Jan. 12 ... the largest independent communications agency focused exclusively on ... focused on helping companies build health-based brands, today ... services agency that works with healthcare and technology ...
... AMERIGROUP Corporation (NYSE: AGP ) announced ... Institute, which will enhance the Company,s focus on improving ... are financially vulnerable, who have disabilities or who are ... a joint venture of AMERIGROUP Corporation and the AMERIGROUP ...
... /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... medical devices worldwide, today announced selected preliminary,unaudited results ... The,preliminary results reported below include the results ... Datascope ("DPM") starting from May,1, 2008. , ...
... Bioequivalence Study to Evaluate the Safety, Tolerability, and ... Laboratories, Inc, an emerging specialty pharmaceutical company dedicated ... in opioid pharmaceuticals, announced today the initiation of ... CL-108. "After many months, development in the ...
Cached Medicine News:Health News:New training method helps surgeons evaluate their own minimally invasive surgery skills 2Health News:Ochsner Baptist Opens ER and Clara Wing 2Health News:Ochsner Baptist Opens ER and Clara Wing 3Health News:Ochsner Baptist Opens ER and Clara Wing 4Health News:WeissComm Group Acquires Strategic Branding Firm ODA and Enters Alliance With Patient-Focused Health Advocacy Strategies to Diversify Business and Expand Offerings 2Health News:WeissComm Group Acquires Strategic Branding Firm ODA and Enters Alliance With Patient-Focused Health Advocacy Strategies to Diversify Business and Expand Offerings 3Health News:AMERIGROUP to Establish Public Policy Institute 2Health News:AMERIGROUP to Establish Public Policy Institute 3Health News:Mindray Announces Preliminary 2008 Operating Results 2Health News:Mindray Announces Preliminary 2008 Operating Results 3Health News:Mindray Announces Preliminary 2008 Operating Results 4Health News:Charleston Laboratories, Inc. Phase I Clinical Trial 2
The AXIUS™ Blower/Mister provides controlled delivery of CO2 and saline to improve visibility during anastomosis....
The RX HERCULINK® PLUS Biliary Stent System is Guidant's high performance .014" guide wire compatible system. It is available in stent diameters of 4.0-6.5mm for the 12mm stent length and 4.0-7.0...
... triaxial catheter design and ergonomic handle ... proprietary radiopaque Nitinol markers on the ... stent enhance visibility. Corrugated ring design ... the nested ring pattern minimizes stent ...
... A particular challenge in transseptal left ... sheath must be exchanged for a sheath ... septal wall position. Traditionally, such an exchange ... a heparinized patient. Biosense Webster has overcome ...
Medicine Products: